NIH Grant Supports Clinical Advancements of FORE-SIGHT(R) Cerebral Oximeter
BRANFORD, Conn., Sept. 17 /PRNewswire-FirstCall/ -- CAS Medical Systems, Inc. (Nasdaq: CASM), a medical device company focused on innovative, non- invasive vital signs monitoring, today announced that it has been awarded a Phase IIb Small Business Innovative Research Grant by the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH),
The three-year grant totaling $2.8 million will be used primarily to support advanced clinical outcome studies that focus on the Company's proprietary LASER-SIGHT(R) technology. This technology is incorporated into the FORE-SIGHT(R) Cerebral Oximeter, which started shipping to distributors and customers in the second quarter of this year. Further clinical studies funded by this grant will be used to expand the clinical applications for FORE-SIGHT outside of the initial target market of high risk cardio-vascular surgery.
"This NIH grant supports the clinical advancement of absolute cerebral oximetry and recognizes the value of CASMED's unique solution to improve patient outcomes," said Andrew E. Kersey, President and CEO of CAS Medical Systems. "We are pleased with our early market response and success with FORE-SIGHT and our customers' understanding of the benefits of absolute cerebral oximetry. We believe the FORE-SIGHT Cerebral Oximeter, featuring our proprietary LASER-SIGHT technology, significantly improves a physician's ability to recognize and correct oxygen deprivation in the brain."
Paul B. Benni, Chief Scientific Officer, added, "The award of this
peer- reviewed grant will enable us to provide physicians with expanded
|SOURCE CAS Medical Systems, Inc.|
Copyright©2007 PR Newswire.
All rights reserved